Christopher Peetz

CEO Christopher Peetz sells 20,000 shares at $121.65–$124.79; retains 194,309 shares plus 108,487 options via scheduled 10b5-1 plan.

Christopher Peetz, CEO of Mirum Pharmaceuticals, executed four separate sales totaling 20,000 shares (20.0K shares) on 2026-07-06 for $2,445,382.04 ($2.4M) at prices ranging from $121.65 to $124.79. The transaction was conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on 2026-03-02, meaning this was a scheduled sale rather than a discretionary decision. Post-transaction, Peetz retains 194,309 shares (194.3K shares) of common stock and holds 108,487 in-the-money employee stock options, preserving substantial equity exposure. Notably, his prior trades at this ticker across five sales on 2026-06-01 have shown 30-day returns ranging from 20.9% to 27.3%, suggesting the stock has had strong momentum—the current price of $128.57 is only 0.3% below the 52-week high despite the blended sale price averaging $122.27. The company remains unprofitable (net income of $-790.2M in the latest full fiscal year) despite significant revenue growth of 54.7% annually, indicating execution risk persists despite recent stock appreciation.

CEO Peetz sells 30,000 shares ($2.9M) via scheduled 10b5-1 plan; retains 194,309 shares plus 128,487 stock options

Christopher Peetz executed 6 separate sales totaling 30,000 shares for $2,875,103.34 at prices ranging from $94.64 to $99.66, reducing his non-derivative holdings from 224,309 to 194,309 shares (-13.4%). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-02, making it scheduled rather than discretionary. The sales occurred as the stock trades at $92.17, down 19.8% from its 52-week high of $114.99, though it is up 30 days (-4.5%) and up 90 days (-0.9%). At MIRM specifically, Peetz's prior 5 sales show mixed near-term outcomes: his most recent sale on 2026-03-16 was followed by 30-day and 90-day gains of 4.8% and 4.7% respectively, while his 2026-02-02 sale saw subsequent declines of 9.9% and 6.6%. The company remains unprofitable (net income of $-790,155,000.00 in the most recent period) despite annual revenue growth of +54.7%, reflecting an early-stage or turnaround profile.

CEO Peetz Christopher sold 40,000 shares of MIRM at $62.00 on 2025-08-11; stock now at $64.72, down from 52-week high of $65.87.

Christopher Peetz, MIRM's CEO, sold 40,000 shares (40.0K shares) for $2,480,000.00 on 2025-08-11, reducing his holdings by 22.4% to 138,641 shares. The sale occurred near the company's 52-week highs ($65.87), with the stock currently trading at $64.72, -1.8% from that peak. Despite near-term weakness and a 30-day return of -6.8% on his cross-ticker sales historically, MIRM itself has rallied +22.9% over 30 days and +45.8% over 90 days post-announcement, placing this sale at a notably inopportune exit point relative to subsequent price action. The company remains unprofitable (net income $-5.9M) despite strong annual revenue growth of +80.8%, and Peetz's prior three measurable sales at MIRM show 2 of 3 were well-timed at the 90-day mark, making this sale's departure from that pattern noteworthy for investors monitoring management conviction.

CEO Christopher Peetz sells 40,000 MIRM shares at $55.25 via 10b5-1 plan adopted Nov 2024

Christopher Peetz, the CEO, sold 40,000 shares on 2025-08-07 at $55.25 per share under a pre-arranged 10b5-1 trading plan adopted on 2024-11-22. This is a scheduled transaction, not a discretionary trade, reducing his holdings from 178,641 shares to 138,641 shares, a reduction of 22.4%. Since the sale is governed by a pre-arranged plan, it reflects predetermined liquidity management rather than a discretionary market-timing decision. The magnitude of the sale—22.4% of pre-transaction holdings—represents a material reduction in his direct stake, which merits monitoring for its effect on CEO alignment with shareholder interests.

CEO Christopher Peetz sells 40,000 shares ($1.9M) at MIRM via pre-arranged 10b5-1 plan adopted Nov 2024

Christopher Peetz, CEO of Mirum Pharmaceuticals, executed 2 separate sales totaling 40,000 shares for $1,876,352.64 on 2025-03-03, reducing his holdings from 155,920 to 115,920 shares (-25.7% reduction). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-22, making it scheduled rather than discretionary. Because the sales were structured under a Rule 10b5-1 plan established months prior, they reflect predetermined execution windows rather than timing-based decision-making. Investors should note the substantial share reduction and monitor filings to understand the plan's overall duration and schedule.